Form 10-Q Editas Medicine, Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Editas Medicine (EDIT) Posts Q1 GAAP Loss of 80c/Share
May 16, 2016 6:29 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.80), which may not compare with the analyst estimate of ($0.30). Revenue for the quarter came in at $805 thousand versus the consensus estimate of $1.08 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More